CSIMarket
 


Fibrogen Inc   (FGEN)
Other Ticker:  
 
 

FGEN's Revenue Growth by Quarter and Year

Fibrogen Inc 's Revenue results by quarter and year




FGEN Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 34.37 16.54 44.03
III Quarter September 40.13 15.74 155.97 42.89
II Quarter June 44.32 29.81 24.36 24.40
I Quarter March 36.16 60.83 38.43 7.97
FY   120.61 140.75 235.30 119.29



FGEN Revenue third quarter 2023 Y/Y Growth Comment
Fibrogen Inc achieved in the third quarter 2023, above Company average Revenue surge of 154.98% year on year, to $ 40.13 millions.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 38 other companies have achieved higher Revenue growth. While Fibrogen Inc ' s Revenue doubling of 154.98% ranks overall at the positon no. 152 in the third quarter 2023.




FGEN Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - 107.8 % -62.43 % 32.74 %
III Quarter September 154.98 % -89.91 % 263.65 % -77.61 %
II Quarter June 48.67 % 22.37 % -0.16 % 2.26 %
I Quarter March -40.56 % 58.29 % 382.18 % -92.62 %
FY   - -40.18 % 97.25 % -66.55 %

Financial Statements
Fibrogen Inc 's third quarter 2023 Revenue $ 40.13 millions FGEN's Income Statement
Fibrogen Inc 's third quarter 2022 Revenue $ 15.74 millions Quarterly FGEN's Income Statement
New: More FGEN's historic Revenue Growth >>


FGEN Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - 118.36 % -89.4 % 2.66 %
III Quarter September -9.44 % -47.2 % 540.27 % 75.78 %
II Quarter June 22.57 % -50.99 % -36.61 % 206.15 %
I Quarter March 5.21 % 267.78 % -12.72 % -75.97 %
FY (Year on Year)   - -40.18 % 97.25 % -66.55 %




Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #39
Healthcare Sector #69
Overall #152

Revenue Y/Y Growth Statistics
High Average Low
335.85 % 35.67 % -92.62 %
(Jun 30 2019)   (Dec 31 2019)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #39
Healthcare Sector #69
Overall #152
Revenue Y/Y Growth Statistics
High Average Low
335.85 % 35.67 % -92.62 %
(Jun 30 2019)   (Dec 31 2019)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Fibrogen Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
702.77 % 78.63 % -89.39 %
(Jun 30 2019)  


FGEN's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Fibrogen Inc disclosed drop in Revenue sequentially by -9.44% to $ 40.13 millions, from $ 44.32 millions released a quarter before.

This is not huge problem, as III. Quarter Revenue frequently seem to dip in the III. Quarter.

Within Major Pharmaceutical Preparations industry 184 other companies have achieved higher Revenue quarter on quarter growth. While Fibrogen Inc 's Revenue growth quarter on quarter, overall rank is 3307.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #185
Healthcare Sector #499
Overall #3307
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #185
Healthcare Sector #499
Overall #3307
Revenue Q/Q Growth Statistics
High Average Low
702.77 % 78.63 % -89.39 %
(Jun 30 2019)  


FGEN's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Fibrogen Inc realized drop in Revenue from the second quarter by -9.44% to $ 40.13 millions, from $ 44.32 millions achived in the previous quarter.

This is not big problem, as Fibrogen Inc 's Revenue frequently gravitate to slow in this quarter Shanaya Rao , an industry researcher noted.

Within Major Pharmaceutical Preparations industry 184 other companies have achieved higher Revenue quarter on quarter growth. While Fibrogen Inc 's Revenue growth quarter on quarter, overall rank is 3307.


Fibrogen Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 154.98 $ 130.58 $ 116.07 $ 140.73 $ 122.91
Y / Y Revenue Growth (TTM) 26.09 % -50.38 % -54.96 % -40.19 % -53.23 %
Year on Year Revenue Growth Overall Ranking # 1556 # 346 # 134 # 141 # 176
Seqeuential Revenue Change (TTM) 18.68 % 12.5 % -17.53 % 14.5 % -53.29 %
Seq. Revenue Growth (TTM) Overall Ranking # 1556 # 2316 # 921 # 2518 # 1803




Cumulative Revenue growth Comment
Fibrogen Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 26.09% year on year, to $ 155 millions if the fiscal year would have ended in Sep 30 2023.
Fibrogen Inc 's trailing twelve months Revenue growth was higher than company's average 14.01% and higher than -50.38% growth in Jun 30 2023.
But from twelve months ended Jun 30 2023 rise was less at 18.68 % from $130.58 millions achieved in twelve months ending a quarter Jun 30 2023 Shanaya Rao  added on.
Still it was validation of convincing trend, as the average Q/Q TTM Revenue gain stands at 14.01%.
The growth is even higher from twelve months ended Jun 30 2023 clinched at 18.68 % jump from $130.58 millions in twelve months ending a quarter before.

In the Healthcare sector 170 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 346 to 1556.

Revenue TTM Q/Q Growth Statistics
High Average Low
142.35 %
14.01 %
-69.24 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 57
Healthcare Sector # 171
Overall # 1556

Revenue TTM Y/Y Growth Statistics
High Average Low
142.35 %
14.01 %
-69.24 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 57
Sector # 171
S&P 500 # 1556
Cumulative Revenue growth Comment
Fibrogen Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 26.09% year on year, to $ 155 millions if the fiscal year would have ended in Sep 30 2023.
Fibrogen Inc 's trailing twelve months Revenue growth was higher than company's average 14.01% and higher than -50.38% growth in Jun 30 2023.
But from twelve months ended Jun 30 2023 increase was less at 18.68 % from $130.58 millions recorded in the period from Jun 30 2023 to Sep 30 2022 Shanaya Rao  continued.
Still it was evidence of strength, while the average Q/Q TTM Revenue advancement lays at 14.01%.
The growth was much stronger sequentially showed at 18.68 % increase from $130.58 millions in twelve months ending a quarter before.

In the Healthcare sector 170 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 346 to 1556.

Revenue TTM Q/Q Growth Statistics
High Average Low
142.35 %
14.01 %
-69.24 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 57
Healthcare Sector # 171
Overall # 1556

Revenue TTM Y/Y Growth Statistics
High Average Low
142.35 %
14.01 %
-69.24 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 57
Sector # 171
S&P 500 # 1556




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
FGEN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for FGEN's Competitors
Revenue Growth for Fibrogen Inc 's Suppliers
Revenue Growth for FGEN's Customers

You may also want to know
FGEN's Annual Growth Rates FGEN's Profitability Ratios FGEN's Asset Turnover Ratio FGEN's Dividend Growth
FGEN's Roe FGEN's Valuation Ratios FGEN's Financial Strength Ratios FGEN's Dividend Payout Ratio
FGEN's Roa FGEN's Inventory Turnover Ratio FGEN's Growth Rates FGEN's Dividend Comparisons



Companies with similar Revenue drop for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Pieris Pharmaceuticals Inc 263.50%$ 263.501 millions
Atai Life Sciences N v 262.50%$ 262.500 millions
Axsome Therapeutics Inc 243.08%$ 243.077 millions
Arcturus Therapeutics Holdings Inc 237.65%$ 237.647 millions
Verve Therapeutics Inc 235.52%$ 235.522 millions
Shattuck Labs Inc 223.58%$ 223.585 millions
Clearside Biomedical Inc 222.93%$ 222.932 millions
Marinus Pharmaceuticals Inc 213.59%$ 213.590 millions
Hookipa Pharma inc 207.94%$ 207.937 millions
Mirati Therapeutics Inc 201.97%$ 201.970 millions
Roivant Sciences Ltd 196.03%$ 196.026 millions
Alnylam Pharmaceuticals Inc 183.96%$ 183.963 millions
Universal Biosensors Inc 181.66%$ 181.659 millions
Foghorn Therapeutics Inc 163.46%$ 163.461 millions
Transmedics Group Inc 158.65%$ 158.654 millions
Anaptysbio inc156.61%$ 156.613 millions
Intelligent Bio Solutions Inc 155.72%$ 155.716 millions
Fibrogen Inc 155.06%$ 155.062 millions
Mirum Pharmaceuticals Inc 154.13%$ 154.127 millions
Bioxcel Therapeutics Inc 148.91%$ 148.905 millions
Palatin Technologies Inc 142.16%$ 142.163 millions
Marizyme Inc 138.82%$ 138.824 millions
Electrocore Inc 128.14%$ 128.138 millions
Intelgenx Technologies Corp 123.94%$ 123.944 millions
Cardiff Oncology inc 119.42%$ 119.419 millions
Aim Immunotech Inc 119.05%$ 119.048 millions
Xencor Inc116.73%$ 116.726 millions
Journey Medical Corporation114.31%$ 114.315 millions
Surmodics Inc113.94%$ 113.941 millions
Agios Pharmaceuticals Inc 110.44%$ 110.438 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com